Indivior prices 0.625% convertible notes due 2031

Indivior Pharmaceuticals, Inc. reported that it has priced an offering of 0.625% convertible senior notes due 2031.

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reported that it has priced an offering of 0.625% convertible senior notes due 2031. These notes are a form of debt that can be converted into shares of Indivior’s common stock under specified conditions.

The company furnished a press release dated March 12, 2026 as Exhibit 99.1, providing additional details on the note offering. The filing clarifies that neither this report nor the press release is an offer to sell or a solicitation to buy the notes or any related common stock.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Indivior (INDV) announce in its latest 8-K filing?

Indivior announced that it has priced an offering of 0.625% convertible senior notes due 2031. These securities are debt instruments that can later be converted into shares of Indivior common stock, potentially affecting the company’s capital structure over time.

What are the key features of Indivior (INDV) 0.625% convertible senior notes?

The notes are senior debt securities bearing a 0.625% interest rate and maturing in 2031. They are convertible into shares of Indivior common stock under specified terms, giving investors both fixed-income characteristics and potential equity exposure in the future.

Does the Indivior (INDV) 8-K filing constitute an offer to sell the notes or stock?

No, the filing explicitly states it is not an offer to sell or a solicitation to buy the notes or any Indivior common stock issuable upon conversion. It serves only to report the pricing and attach the related press release for regulatory disclosure purposes.

What additional information does Indivior (INDV) provide about the note offering?

Indivior includes a press release dated March 12, 2026 as Exhibit 99.1, which contains further details about the 0.625% convertible senior notes due 2031. Investors can review this exhibit to better understand the structure and terms of the offering.

On which exchange is Indivior (INDV) common stock listed?

Indivior’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol INDV. The convertible notes described in the filing may be converted into shares of this listed common stock.

Which items and exhibits are included in the Indivior (INDV) 8-K?

The report uses Item 8.01 for Other Events to describe the pricing of the convertible notes. It lists Exhibit 99.1 as the press release dated March 12, 2026 and Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 08:42 PM Learn about SEC filing dates

0001625297FALSE00016252972026-03-122026-03-1300016252972026-03-032026-03-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2026

INDIVIOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-37835			41-2520873
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10710 Midlothian Turnpike, Suite 125 North Chesterfield, VA						23235
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: 804-379-1090

not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value per share

INDV

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 8.01 Other Events.

On March 12, 2026, the Company announced the pricing of its offering of 0.625% convertible senior notes due 2031 (the “Notes”). A copy of the press release is filed as 99.1 to this Current Report on Form 8-K.

Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.

Item 9.01 Exhibits

(d) Exhibits.

Exhibit No.						Description
99.1						Press release dated March 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Indivior Pharmaceuticals, Inc.
Date: March 12, 2026			By:			/s/ Ryan Preblick
						Name: Ryan Preblick
						Title: Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 15.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB